Trials / Completed
CompletedNCT00575562
Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Kyowa Kirin, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the safety and tolerability of KRN330 in patients with relapsed or refractory advanced or metastatic colorectal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KRN330 | Open-label, dose-escalation study of KRN330 in patients with relapsed or refractory advanced or metastatic colorectal cancer |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2010-01-01
- Completion
- 2010-01-01
- First posted
- 2007-12-18
- Last updated
- 2024-04-29
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00575562. Inclusion in this directory is not an endorsement.